PMID- 9568736
OWN - NLM
STAT- MEDLINE
DCOM- 19980611
LR  - 20240109
IS  - 0021-9150 (Print)
IS  - 0021-9150 (Linking)
VI  - 137
IP  - 1
DP  - 1998 Mar
TI  - The antioxidative effects of the isoflavan glabridin on endogenous constituents 
      of LDL during its oxidation.
PG  - 49-61
AB  - The effect of the consumption of glabridin, an isoflavan isolated from 
      Glycyrrhiza glabra (licorice) root, on the susceptibility of low density 
      lipoprotein (LDL) to oxidation was studied in atherosclerotic apolipoprotein E 
      deficient (E[o] mice) and was compared with that of the known flavonoids, 
      quercetin and catechin. Glabridin inhibitory activity on in vitro oxidation of 
      human LDL was also investigated by determining the formation of lipid peroxides 
      and oxysterols and the consumption of LDL-associated lipophilic antioxidants. 
      Determination of the extent of LDL oxidation by measuring the formation of 
      thiobabituric acid reactive substances (TBARS) after 2 h of LDL incubation with 
      CuSO4 (10 microM) or 2,2'-azobis (2-amidino-propane) dihydrochloride (AAPH) (5 
      mM), revealed that glabridin or quercetin consumption resulted in a 53 and 54% 
      reduction in copper ion induced oxidation, respectively, and a 95 and 83% 
      reduction in AAPH induced LDL oxidation, respectively. No inhibition was obtained 
      with consumption of catechin. About 80% of glabridin was found to bind to the LDL 
      human particle. In the in vitro oxidation of LDL induced by AAPH (5 mM), 
      glabridin inhibited the formation of TBARS, lipid peroxides and cholesteryl 
      linoleate hydroperoxide (CLOOH) at all the concentrations tested (5-60 microM), 
      while in oxidation induced by copper ions (10 microM), glabridin exhibited a 
      pro-oxidant activity at concentrations lower than 20 microM, and a clear 
      antioxidant activity at concentrations greater than 20 microM. Glabridin (30 
      microM) inhibited the formation of cholest-5-ene-3,7-diol (7-hydroxycholesterol), 
      cholest-5-ene-3-ol-7-one (7-ketocholesterol) and cholestan-5,6-epoxy-3-ol 
      (5,6-epoxycholesterol) after 6 h of AAPH induced LDL oxidation, by 55, 80 and 
      40%, respectively, and after 6 h of copper ion induced LDL oxidation, by 73, 94 
      and 52%, respectively. Glabridin also inhibited the consumption of beta-carotene 
      and lycopene by 38 and 52%, respectively, after 0.5 h of LDL oxidation with AAPH, 
      but failed to protect vitamin E. The in vivo and in vitro reduction of the 
      susceptibility of LDL to oxidation obtained with glabridin, may be related to the 
      absorption or binding of glabridin to the LDL particle and subsequent protection 
      of LDL from oxidation by inhibiting the formation of lipid peroxides and 
      oxysterols, and by protecting LDL associated carotenoids.
FAU - Belinky, P A
AU  - Belinky PA
AD  - Laboratory of Natural Compounds for Medical Use, Migal, Galilee Technological 
      Center, Kiryat Shmona, Israel.
FAU - Aviram, M
AU  - Aviram M
FAU - Fuhrman, B
AU  - Fuhrman B
FAU - Rosenblat, M
AU  - Rosenblat M
FAU - Vaya, J
AU  - Vaya J
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 0 (Amidines)
RN  - 0 (Antioxidants)
RN  - 0 (Chelating Agents)
RN  - 0 (Flavones)
RN  - 0 (Flavonoids)
RN  - 0 (Free Radical Scavengers)
RN  - 0 (Isoflavones)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Oxidants)
RN  - 0 (Phenols)
RN  - 0 (Sterols)
RN  - 01YAE03M7J (beta Carotene)
RN  - 1406-18-4 (Vitamin E)
RN  - 36-88-4 (Carotenoids)
RN  - 7381JDR72F (2,2'-azobis(2-amidinopropane))
RN  - 789U1901C5 (Copper)
RN  - 8R1V1STN48 (Catechin)
RN  - 9IKM0I5T1E (Quercetin)
RN  - E1UOL152H7 (Iron)
RN  - HOC5567T41 (glabridin)
RN  - S2V45N7G3B (flavone)
RN  - SB0N2N0WV6 (Lycopene)
SB  - IM
MH  - Amidines/antagonists & inhibitors/pharmacology
MH  - Animals
MH  - Antioxidants/administration & dosage/*pharmacology
MH  - Carotenoids/metabolism
MH  - Catechin/administration & dosage/pharmacology
MH  - Chelating Agents/administration & dosage/pharmacology
MH  - Copper/antagonists & inhibitors/pharmacology
MH  - Dietary Supplements
MH  - Dose-Response Relationship, Drug
MH  - Flavones
MH  - Flavonoids/administration & dosage/pharmacology
MH  - Free Radical Scavengers/administration & dosage/pharmacology
MH  - Iron/antagonists & inhibitors
MH  - Isoflavones
MH  - Lipid Peroxidation/*drug effects
MH  - Lipoproteins, LDL/*drug effects/*metabolism
MH  - Lycopene
MH  - Mice
MH  - Mice, Mutant Strains
MH  - Oxidants/antagonists & inhibitors/pharmacology
MH  - Oxidation-Reduction/drug effects
MH  - Phenols/administration & dosage/metabolism/*pharmacology
MH  - Protein Binding
MH  - Quercetin/administration & dosage/pharmacology
MH  - Sterols/metabolism
MH  - Time Factors
MH  - Vitamin E/metabolism
MH  - Vitamin E Deficiency/drug therapy/genetics
MH  - beta Carotene/metabolism
EDAT- 1998/05/06 00:00
MHDA- 1998/05/06 00:01
CRDT- 1998/05/06 00:00
PHST- 1998/05/06 00:00 [pubmed]
PHST- 1998/05/06 00:01 [medline]
PHST- 1998/05/06 00:00 [entrez]
AID - S0021-9150(97)00251-7 [pii]
AID - 10.1016/s0021-9150(97)00251-7 [doi]
PST - ppublish
SO  - Atherosclerosis. 1998 Mar;137(1):49-61. doi: 10.1016/s0021-9150(97)00251-7.